2021 Pediatric Grand Rounds | Molecular Risk Stratification of Rhabdomyosarcoma

Duarte, CA US
July 29, 2021

Rhabdomyosarcoma is traditionally risk stratified based on clinical features. With the advent of molecular profiling, multiple molecular markers of adverse prognosis has been recognized in rhabdomyosarcoma. The next step is to combine these markers to clinical factors to refine rhabdomyosarcoma risk stratification.    

Target Audience

City of Hope Pediatric Hematology/Oncology physicians, advance practice practitioners, City of Hope staff and research teams.

Learning Objectives

  • Outline the molecular prognostic factors in fusion negative and fusion positive rhabdomyosarcoma.
  • Identify opportunities for therapy reduction and therapy intensification in different subgroups of rhabdomyosarcoma.
  • Discuss the potential role of whole genome sequencing and methylation array analysis in newly diagnosed patients with rhabdomyosarcoma.
  • Integrate genomic testing into rhabdomyosarcoma management where appropriate.
  • Outline the various types of cultural diversities (gender, age, race, religion, culture, etc.) that relate to demographics, diagnosis and treatment.
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2021 Pediatric Grand Rounds | Molecular Risk Stratification of Rhabdomyosarcoma for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Activity opens: 
07/29/2021
Activity expires: 
07/30/2021
Event starts: 
07/29/2021 - 12:00pm
Event ends: 
07/29/2021 - 1:00pm
City of Hope
1500 E Duarte Rd
Duarte, CA 91010
United States

Virtual Meeting- Zoom

Rajkumar Venkatramani, MD, MS, MBA, FAAP   Associate Professor; Director of Clinical Business Operations; Texas Children's Cancer and Hematology Centers; Director, Solid Tumor Program; Director, Rare Tumors Program; Chair, COG Soft Tissue Sarcoma Committee; Baylor College of Medicine

Dr. Venkatramani has indicated that he does not have anything to disclose.

ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: City of Hope designates this live webinar for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The following credit type(s) are being offered for this course:

 AMA PRA Category 1™  1.0

The following may apply AMA PRA Category 1 Credit™ for license renewal:

Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.

Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2021 Pediatric Grand Rounds | Molecular Risk Stratification of Rhabdomyosarcoma for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Please login or register to take this activity.